Dr. Nghiem is discovering new ways to prevent and treat skin cancers
by studying the systems that control cell division. These systems help
prevent cells with damaged DNA from reproducing and, when they
malfunction, can affect cells’ chances of becoming cancerous.
One part of such systems is an enzyme called ATR. Dr. Nghiem
demonstrated that caffeine can protect against the cancer-causing
effects of ultraviolet light by interfering with ATR and leading damaged
cells to self-destruct. He is now investigating the mechanisms behind
this effect, with the goal of gaining insights into ways to harness these
mechanisms to better prevent skin cancer.
Dr. Nghiem is one of the world’s foremost experts on a rare, deadly
and difficult-to-treat skin cancer called Merkel cell carcinoma. His
research has identified genetic mutations that may drive MCC and
shed light on how a specific virus may trigger tumor development.
As a pioneer of immunotherapy for MCC, his team leads an earlyphase
clinical trial that uses MCC patients’ own immune cells to target
the cancer. Another ongoing trial explores the use of a molecule
designed to stimulate patients’ immune systems. Encouraging initial
results suggest that immunotherapies may be potent strategies for
treating this disease.
Dr. Nghiem has studied methods to differentiate and treat different
types of skin inflammation, including graft-vs.-host disease (when
transplanted tissues attack the body) and eczema.
As a practicing physician, Dr. Nghiem treats patients with melanoma,
MCC and other skin cancers at Seattle Cancer Care Alliance.
Honors / Awards
Elected in 2014 to the American Society for Clinical Investigation
American Cancer Society Legacy & Leadership Award: Find Cures Award in 2012
George F. Odland Endowed Chair in Dermatology at UW, 2015
Dr. Paul Nghiem explains how his team uses immunotherapy to combat a rare, often misdiagnosed form of skin cancer. Nghiem is affiliate investigator in Fred Hutch’s Clinical Research Division, head of dermatology at the University of Washington and director of the Skin Oncology Clinical Program at Seattle Cancer Care Alliance. To arrange an interview with Dr. Nghiem, please contact media relations at (206) 667-2210 or email email@example.com.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.